## Product Datasheet

# EW-7195

Catalog No. **BP-01875** · CAS **1352609-28-9** · Form **free base** · Physical state **solid** · Color **off-white to light yellow** · Version **1.0** · Revision **2026-09-07**

**FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.**

| Target | Research area |
|---|---|
| **TGF-β Receptor; p38 MAPK** | **Cancer** |

| | |
|---|---|
| Molecular formula | $C_{23}H_{18}N_8$ |
| Molecular weight | **406.4426** |

**STRUCTURE**




## DESCRIPTION

EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC50 of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung.

## BIOLOGICAL ACTIVITY

In Vitro

EW7195 inhibits the EMT, motility, and invasiveness of breast cancer cells in vitro. EW-7195 efficiently blocks TGF-β1-induced phosphorylation of Smad2 followed by the nuclear translocation of Smad2/3. EW-7195 blocks TGF-β1-induced mesenchymal morphology. EW-7195 inhibits TGF-β-induced transcriptional activation.

EW-7195 (0.5-1 μM; 1.5 hours) efficiently inhibits TGF-β1-induced Smad2 phosphorylation.

In Vivo

EW7195 (40 mg/kg; i.p.; three times a week for 3/2.5 weeks) inhibits lung metastasis development in both 4T1 orthotopic xenograft and MMTV/cNeu transgenic mice.

## SOLUBILITY

Soluble in DMSO : 50 mg/mL

## REFERENCES

[1]. Park CY, et al. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. Eur J Cancer. 2011;47(17):2642-2653.